NRX Pharmaceuticals, Inc. — Director's Dealing 2026

Feb 17, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NRX Pharmaceuticals, Inc. (NRXP)
CIK: 0001719406
Period of Report: 2026-01-27

Reporting Person: Casper Joseph Michael (Chief Operating Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-01-27	Stock Option (right to buy)	$2.39	A	100000	Acquired	2036-01-27	Common Stock (100000)	Direct

Footnotes

F1: Represents stock options ("Options") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. 33.3% of the Options shall vest on June 1, 2026, 33.3% shall vest on December 1, 2026, and the remaining 33.3% shall vest on December 1, 2027.